130 related articles for article (PubMed ID: 37619953)
1. Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation.
Plavec TV; Klemenčič K; Kuchař M; Malý P; Berlec A
Eur J Pharm Sci; 2023 Nov; 190():106568. PubMed ID: 37619953
[TBL] [Abstract][Full Text] [Related]
2. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.
Škrlec K; Zadravec P; Hlavničková M; Kuchař M; Vaňková L; Petroková H; Křížová L; Černý J; Berlec A; Malý P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29966384
[TBL] [Abstract][Full Text] [Related]
3. Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.
Kosler S; Strukelj B; Berlec A
Curr Pharm Biotechnol; 2017; 18(4):318-326. PubMed ID: 28190384
[TBL] [Abstract][Full Text] [Related]
4. Engineered
Plavec TV; Kuchař M; Benko A; Lišková V; Černý J; Berlec A; Malý P
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137908
[No Abstract] [Full Text] [Related]
5. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.
Kuchař M; Vaňková L; Petroková H; Cerný J; Osička R; Pelák O; Sípová H; Schneider B; Homola J; Sebo P; Kalina T; Malý P
Proteins; 2014 Jun; 82(6):975-89. PubMed ID: 24549990
[TBL] [Abstract][Full Text] [Related]
6. Dual Functionalized
Zahirović A; Plavec TV; Berlec A
Front Bioeng Biotechnol; 2022; 10():822823. PubMed ID: 35155394
[TBL] [Abstract][Full Text] [Related]
7. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
Wang J; Tian M; Li W; Hao F
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
[TBL] [Abstract][Full Text] [Related]
8. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
9. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells.
Křížová L; Kuchař M; Petroková H; Osička R; Hlavničková M; Pelák O; Černý J; Kalina T; Malý P
Autoimmunity; 2017 Mar; 50(2):102-113. PubMed ID: 28100093
[TBL] [Abstract][Full Text] [Related]
10. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
11. ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.
Hlavničková M; Kuchař M; Osička R; Vaňková L; Petroková H; Malý M; Černý J; Arenberger P; Malý P
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304852
[TBL] [Abstract][Full Text] [Related]
12. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit.
Zadravec P; Marečková L; Petroková H; Hodnik V; Perišić Nanut M; Anderluh G; Štrukelj B; Malý P; Berlec A
PLoS One; 2016; 11(9):e0162625. PubMed ID: 27606705
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.
Zahirović A; Berlec A
Microb Cell Fact; 2022 Jul; 21(1):143. PubMed ID: 35842694
[TBL] [Abstract][Full Text] [Related]
14. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
15. Expression of biologically active murine interleukin-18 in Lactococcus lactis.
Feizollahzadeh S; Khanahmad H; Rahimmanesh I; Ganjalikhani-Hakemi M; Andalib A; Sanei MH; Rezaei A
FEMS Microbiol Lett; 2016 Nov; 363(21):. PubMed ID: 27864297
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization.
Li HS; Piao DC; Jiang T; Bok JD; Cho CS; Lee YS; Kang SK; Choi YJ
Vaccine; 2015 Apr; 33(16):1959-67. PubMed ID: 25738814
[TBL] [Abstract][Full Text] [Related]
17. Invasive Lactococcus lactis producing mycobacterial Hsp65 ameliorates intestinal inflammation in acute TNBS-induced colitis in mice by increasing the levels of the cytokine IL-10 and secretory IgA.
da Cunha VP; Preisser TM; Santana MP; Machado DCC; Pereira VB; Miyoshi A
J Appl Microbiol; 2020 Nov; 129(5):1389-1401. PubMed ID: 32473073
[TBL] [Abstract][Full Text] [Related]
18. Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells.
Škrlec K; Pucer Janež A; Rogelj B; Štrukelj B; Berlec A
Microb Biotechnol; 2017 Nov; 10(6):1732-1743. PubMed ID: 28736998
[TBL] [Abstract][Full Text] [Related]
19. Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.
Parlane NA; Grage K; Lee JW; Buddle BM; Denis M; Rehm BH
Appl Environ Microbiol; 2011 Dec; 77(24):8516-22. PubMed ID: 21984246
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of intestinal inflammation in IL-10 deficient mice by a plasmid carrying Lactococcus lactis strain.
Zurita-Turk M; Mendes Souza B; Prósperi de Castro C; Bastos Pereira V; Pecini da Cunha V; Melo Preisser T; Caetano de Faria AM; Carmona Cara Machado D; Miyoshi A
BMC Biotechnol; 2020 Jul; 20(1):38. PubMed ID: 32703192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
